Taro Pharmaceutical Industries stock faces a legal settlement
Published on 09/24/2026 at 17:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Taro Pharmaceutical Industries stock stood at USD 42.98 on the NYSE on September 7, 2026, up 0.01 percent from the prior close, while volume reached 147,064 shares. The latest company-related event is a US generic drug pricing settlement involving Taro and its US subsidiary.
Settlement terms stay confidential
As CNBC TV18 reported on September 11, 2026, Taro Pharmaceutical Industries and Taro Pharmaceuticals U.S.A. signed a settlement agreement with a plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation. The case is before the US District Court for the Eastern District of Pennsylvania.
The agreement requires the subsidiaries to make a settlement payment in exchange for a full release of claims. The financial terms and other settlement details were kept confidential, so the market impact cannot be measured through a disclosed payment amount.
The ticker carries corporate action risk
A corporate action entry from Robinhood lists October 22, 2025, as the date of a cash merger for Taro Pharmaceutical Industries. It states that shares were removed and shareholders received USD 32.2500 per share in cash.
That cash consideration is USD 10.7300 below the USD 42.98 market snapshot from September 7, 2026, a difference of 33.4 percent. The mismatch makes the corporate action record more important than a standalone quote when assessing the ticker's status.
Product recall adds operating context
An updated September 1, 2026 report by Medical Daily described a voluntary Class II recall involving 1,968 bottles of Taro-manufactured Carbamazepine Tablets USP, 200 mg. The prescription bottles contained 1,000 tablets each and were distributed nationwide.
For investors, the figures point to two separate issues: the settlement creates legal context, while the corporate action record defines the economic outcome for shareholders. The September 7 quote also showed a day range of USD 42.94 to USD 42.98 and trading volume 347.0 percent above its average.
Stock snapshot remains historical
Taro Pharmaceutical Industries stock was quoted at USD 42.98 on the NYSE on September 7, 2026. The dated snapshot sits alongside the USD 32.2500 cash consideration listed for October 22, 2025, making the corporate action timeline central to interpreting the security.
Taro Pharmaceutical Industries at a glance
- Company: Taro Pharmaceutical Industries Ltd.
- Ticker: TARO
- Trading venue: NYSE
- Price as of September 7, 2026: USD 42.98
- Sector / Industry: Health Care / Pharmaceuticals
